In the first Level-I study regarding non-union† heal rates, 51 patients with tibia delayed unions were treated with EXOGEN. Mean improvement in their bone mineral density was 1.34 times greater than that of patients who received sham device treatment.
This white paper 23 evaluates the expected cost of treating a non-union* fracture using five fracture stimulation devices. Researchers determine that EXOGEN is the most cost-effective treatment and is optimal for 85% of patients.
Download white paper.
In this study,13 researchers compare three economic models for treating a pool of 1,000 patients with tibia fractures. Using EXOGEN in conservative and operative treatment paths resulted in an overall savings of $14.6 million—a reduction in cost that would benefit third-party payers, employers, government agencies and patients.